Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds

Clinical Therapeutics

Volumn 39, Issue 10, 2017, Pages 2024-2037

  Gantz, Ira ^a   Sokolova, Liubov ^b   Jain, Lokesh ^a   Iredale, Carol ^a   O'Neill, Edward A ^a   Wei, Ziwen ^a   Lam, Raymond ^a   Suryawanshi, Shailaja ^a   Kaufman, Keith D ^a   Engel, Samuel S ^a   Lai, Eseng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

Author keywords

confounder in clinical research; failed clinical trial; incretin therapy; MK 3102; oral antihyperglycemic agent; patient nonadherence to the protocol

Indexed keywords

AMYLASE; CREATINE KINASE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; OMARIGLIPTIN; PLACEBO; TRIACYLGLYCEROL LIPASE; 2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)-2,6-DIHYDROPYRROLO(3,4-C)PYRAZOL-5(4H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSED HETEROCYCLIC RINGS; GLYCOSYLATED HEMOGLOBIN; PYRAN DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HICCUP; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADOLESCENT; ANALYSIS; BLOOD; COMBINATION DRUG THERAPY; EPIDEMIOLOGY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCATED HEMOGLOBIN A; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; PYRANS; YOUNG ADULT;

EID: 85029481797     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.08.009     Document Type: Article

References (11)

1. Biftu, T., Sinha-Roy, R., Chen, P., et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem 57 (2014), 3205–3212.
2. Gantz, I., Okamoto, T., Ito, Y., et al. Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial. Diabetologia, 57, 2014, S55.
3. Gantz, I., Lai, E., Suryawanshi, S., et al. Omarigliptin, a once-weekly DPP-4 inhibitor, provides similar glycemic control to sitagliptin in patients with T2DM inadequately controlled on metformin. Diabetologia 58 (2015), S54–S55.
4. Liang, K.Y., Zeger, S.L., Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian J Statistics 62 (2000), 134–148.
5. Sheu, W.H., Gantz, I., Chen, M., et al. Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care 38 (2015), 2106–2114.
6. Goldenberg, R., Gantz, I., Andryuk, P.J., et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 19 (2017), 394–400.
7. Lee, S.H., Gantz, I., Round, E., et al. Omarigliptin, a once-weekly DPP-4 inhibitor, improves glycemic control in patients inadequately controlled on the combination of metformin and glimepiride. Diabetes, 65, 2016, A50.
8. Gantz, I., Okamoto, T., Sato, A., et al. Omarigliptin improves glycemic control and is well tolerated as add-on therapy to oral antihyperglycemic agents in Japanese patients with type 2 diabetes. Diabetes 64 (2015), A318–A319.
9. Dresser, R., Subversive subjects: rule-breaking and deception in clinical trials. J Law Med Ethics 41 (2013), 829–840.
10. Clark, D.B., Taylor, C.B., Roth, W.T., et al. Surreptitious drug use by patients in a panic disorder study. Am J Psychiatry 147 (1990), 507–509.
11. Devine, E.G., Waters, M.E., Putnam, M., et al. Concealment and fabrication by experienced research subjects. Clin Trials 10 (2013), 935–948.